GlassScriptPhysician profile
Spencer Hansen
NPI 1164954814
$4,058.16
in general payments reported to CMS, 2019-2025
24 companies · $1,551 in 2025
The $1,551 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $140 · 2023: $504 · 2024: $1,863 · 2025: $1,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,863 · Education: $54.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,863.34 |
| Education | $54.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,462.30 | 2023-2025 | |
| Janssen Biotech, INC. | $580.69 | 2023-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $359.76 | 2023-2025 | Xifaxan, Plenvu, Trulance |
| Genzyme Corporation | $247.30 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $236.82 | 2023-2025 | Voquezna |
| Lilly USA, LLC | $233.72 | 2024-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $217.63 | 2024-2025 | Iqirvo, Bylvay |
| Takeda Pharmaceuticals U.S.A., INC. | $144.25 | 2023-2025 | Eohilia, Gattex |
| Medtronic, INC. | $140.16 | 2022 | |
| Qol Medical, LLC | $86.79 | 2023-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $48.27 | 2023-2024 | Linzess |
| Pfizer INC. | $43.23 | 2024-2025 | |
| Celltrion USA INC. | $40.90 | 2024 | Zymfentra |
| Novo Nordisk INC | $34.88 | 2025 | Wegovy |
| Amgen INC. | $24.72 | 2023 | Avsola, Amjevita |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $22.01 | 2024 | Dupixent |
| Orphalan INC | $21.83 | 2024 | Cuvrior |
| Enterra Medical, INC. | $20.39 | 2023 | |
| Cook Medical LLC | $18.46 | 2025 | Hemospray |
| Braintree Laboratories, INC. | $16.74 | 2024 | Sutab, Suflave |
| Ardelyx, INC. | $15.03 | 2025 | Ibsrela |
| Olympus America INC. | $14.38 | 2023 | Endoclot Phs |
| Madrigal Pharmaceuticals | $14.29 | 2024 | Resmetirom |
| Daiichi Sankyo INC. | $13.61 | 2024 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Spencer Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.